



Hepatitis C virus (HCV) infection is an important cause of major morbidities including chronic liver disease, liver 
cancer, acute kidney injury and chronic kidney disease (CKD). Among patients with kidney disease who have HCV 
infection, the clinical outcomes are worse. The prevalence of HCV infection is exceptionally high among dialysis and 
kidney transplant patients throughout the globe. It is estimated that 5% to 25% or more of dialysis-dependent 
patients are affected. Almost half of all deaths in CKD patients, including HCV-infected patients, are due to 
cardiovascular disease, and HCV-infected patients have higher mortality. Given the importance and impact of 
the HCV epidemic on global kidney health, and the status of Egypt as the nation with the highest prevalence of 
HCV infection in the world along with its initiatives to eradicate HCV, the International Federation of Kidney 
Foundations convened a consensus conference in Cairo in December 2017. This article reflects the opinions and 
recommendations of the contributing experts and reiterates that, with the current availability of highly effective 
and well tolerated pharmacotherapy, CKD patients should be given priority for the treatment of HCV, as an 
important step towards the World Health Organization’s goal of eliminating viral hepatitis as a public health problem 
by 2030.
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INtrODUctION
The 69th World Health Assembly approved the Global 
Health Sector Strategy to eliminate viral hepatitis by 2030, 
with special emphasis on hepatitis C virus (HCV) infection, 
a goal which can become a reality with the recent launch of 
direct-acting antiviral (DAA) therapies [1].  There were an 
estimated 80 million HCV infections in 2013; the 2015 
global prevalence of 1.0%, or 71 million infections, is lower, 
largely due to lower prevalence estimates in Africa [2]. 
Additionally, the mortality due to liver-related causes and 
an ageing population may have contributed to a reduction 
in the total number of HCV infections. The genotype 
distribution, by region, has not changed substantially since 
the Global Burden of Disease (GBD) study [2].  Genotype 
1 accounts for most cases in Europe, North and South 
America as well as China and Russia, whereas genotype 3 
is the most prevalent in the Indian subcontinent, and 
genotypes 4 and 5 are more prevalent in some African 
countries [3].
Viral hepatitis ranked 7th among mortality causes in the 
GBD analysis, much higher than in the 1990 analysis, and its 
global impact exceeds that of  HIV infection, tuberculosis 
or malaria [2]. This increased burden of viral hepatitis is 
compatible with the long interval (generally decades) 
between HCV infection and serious complications such as 
cirrhosis, hepatocellular carcinoma or death. The GBD 
study may have underestimated the deleterious impact of 
HCV [2]. This may be due to the scarcity of reliable data 
from some regions of the world where estimates depend 
largely on extrapolation rather than surveillance of seroposi-
tivity and accurate recording of the aetiology of chronic 
liver disease.
Recent evidence increasingly points to the fact that, beyond 
the effect on liver disease, HCV infection is a systemic 
disease with significant cardiovascular and renal impact, not 
ascribed in the GBD analysis to HCV [4].
It is against this background that the International Federa-
tion of Kidney Foundations convened a conference of 
experts in nephrology, gastroenterology and hepatology in 
Cairo, Egypt, in 2017 to review the evidence and develop 
recommendations for the management of HCV in patients 
with chronic kidney disease (CKD).
sUccEss IN tHE GLObAL ErADIcAtION 
OF HcV
HCV is an ideal target for eradication since there is no non-
human reservoir of the virus and pharmacologic treatment 
with DAAs can cure infected persons. However, re-infec-
tion is possible until the risks of transmission can be elimi-
nated or an effective vaccine is available. Although the 
biology of HCV and the availability of DAAs favour the 
feasibility of HCV elimination, there are serious barriers to 
achieving this result. For example, there is a high prevalence 
of HCV infection in “difficult-to-reach” populations, such as 
people who inject drugs and the homeless, as well as 
marginalized groups such as incarcerated people and 
refugees [5].
tHE PrEVENtION OF NOsOcOMIAL  
HcV trANsMIssION WItHIN 
HAEMODIALYsIs UNIts
Patients on haemodialysis (HD) have long been known to 
be among the groups at highest risk for HCV infection. 
Recent figures from the Dialysis Outcomes and Practice 
Patterns Study  (DOPPS) indicate that the annual incidence 
of seroconversion for HCV averages 1.2%,  suggesting that 
at least 20,000 cases of HCV are acquired worldwide 
within HD units each year [6]. The main routes for HCV 
transmission in HD units are parenteral administration of 
drugs contaminated with traces of HCV-infected blood and 
the invisible contamination by blood of external surfaces 
and the hands of staff [7] . 
Thus, the application of basic hygiene precautions is crucial. 
These include hand hygiene before contact with patients 
and after removal of gloves, changing gloves between 
patients or dialysis stations, preparing injectable drugs in a 
clean area and cleaning and disinfecting surfaces of the 
HD environment before the next treatment session [6]. 
The 2018 update of the Kidney Disease: Improving Global 
Outcomes (KDIGO) clinical practice guideline for the 
prevention, diagnosis, evaluation, and treatment of hepatitis 
C in CKD reiterates that isolation of HCV-positive patients 
is not required if attention is devoted to these simple 
precautions [8]. 
HCV infection is associated with higher risk of death among 
dialysis patients [9]. Markers of the malnutrition–inflam-
mation–cachexia syndrome, rather than traditional cardio-
vascular risk factors, are among the strongest predictors of 
early death in these patients; the impact of HCV infection 
on nutritional status and inflammation may be an important 
cause of poor survival in this population. 
Diagnosis and detection of HcV in cKD and 
haemodialysis patients 
KDIGO recommends screening all CKD patients for 
HCV, using an immunoassay, at the time of diagnosis of 
CKD [10]. If the immunoassay is positive, then nucleic 
acid testing (NAT) is recommended. For patients starting 
haemodialysis, screening for HCV using either an 
Hepatitis c virus infection and global kidney health
162
immunoassay or NAT is recommended. In all cases, if the 
immunoassay is positive, then NAT testing is recommended. 
The recommended interval for retesting patients on 
haemodialysis is every 6 months. If a new case of HCV is 
diagnosed in a dialysis centre, testing of all patients is 
recommended [10]. The implementation of this guideline 
has some variability across different world regions. In the 
Asia Summit Conference report, most participating 
countries reported implementing the same guideline. 
However, in some countries testing for the HCV core 
antigen is used as an alternative due to the lower cost. The 
frequency of repeat testing varied from every 3 months to 
yearly [11].
rEsPONsE tO HcV trEAtMENt AND 
crItErIA FOr cUrE
Treating HCV infection early is the most effective way to 
prevent clinical complications of the infection [12]. The 
new drugs have made cure possible; sustained virologic 
response is achieved in more than 95% of patients within a 
relatively short period (≤12 weeks) and the treatment can 
also improve liver histology. DAA regimens have few or 
mild side effects. It must be noted that, although effective 
treatment is now available, its impact will be insignificant 
without implementing expanded procedures for screening, 
disease surveillance and appropriate management.
The goal of treatment is to reduce all-cause mortality and 
adverse liver-related health consequences, including end-
stage liver disease (ESLD) and hepatocellular carcinoma 
(HCC), by the achievement of virologic cure as evidenced 
by a sustained virologic response (SVR) [2]. The benefits of 
cure include improvements in liver inflammation, portal 
hypertension, extra-hepatic manifestations, cryoglobuli-
naemia, diabetes and improved outcomes of kidney 
transplantation. There is also growing evidence that 
cardiovascular risk is reduced [1,13]. 
Virologic cure, defined as the absence of detectable HCV 
RNA at least 12 weeks after completion of therapy, is 
durable in more than 99% of patients followed up for 
≥5 years. HCV RNA detection and quantification requires 
a sensitive assay, such as the FDA-approved quantitative 
NAT, which has a lower limit of detection of  ≤15 IU/mL 
[14]. Sustained virologic responses at 12 months (SVR12) 
and 24 months (SVR24) have both been accepted as 
endpoints of therapy by regulators in the United States and 
Europe, given that their concordance is >99% [15]. 
Patients who achieve an SVR do not need to be retested 
for HCV unless they remain at risk of reinfection 
(e.g. haemodialysis patients and patients who inject drugs). 
Re-infection due to high-risk behaviour may negate the 
benefits of treatment. Reported rates of re-infection 
following successful HCV treatment among patients at 
high risk vary from 1–8% per year. Cirrhotic patients who 
achieve an SVR should remain under life-long surveillance 
for the development of HCC and for the development of 
oesophageal varices [2]. 
HEPAtItIs c VIrUs AND   
KIDNEY DIsEAsEs
HCV can cause kidney disease in at least four different 
ways: 1) glomerular immune complex deposition, 2) direct 
viral invasion of renal parenchyma, 3) renal complications 
of chronic liver disease, and 4) complications related to 
the antiviral treatment. These mechanisms interact in the 
pathogenesis of several acute and chronic clinical renal 
syndromes [16].
HEPAtItIs c AND AcUtE  
KIDNEY INJUrY
HCV infection can cause acute kidney injury (AKI) in several 
ways. The best known and most common is cryoglob-
ulinaemic vasculitis. This has been reported in 1–5% of 
patients with chronic HCV infection [2]. Risk factors include 
female gender, older age, heavy alcohol consumption, 
longer duration of infection, type II mixed cryoglobulinaemia, 
high cryoglobulin serum levels, low complement (C4) 
levels, HCV genotypes 2 or 3 and extensive liver fibrosis. 
Genetic and epigenetic factors appear to have a significant 
role. AKI is clinically associated with oliguria, haematuria 
and extrarenal manifestations of cryoglobulinaemia, mainly 
peripheral neuropathy, arthralgias and a characteristic 
purpuric rash (Meltzer’s triad). Renal biopsy confirms the 
diagnosis by the combination of vasculitic lesions, glomerular 
fibrinoid necrosis with cryoglobulinaemic thrombi and 
tubular casts. Glomerular crescents are common. In 1/6 of 
cases, the disease progresses rapidly to fatal systemic 
thrombotic microangiopathy (TMA) with pulmonary and 
cerebral vasculitis (catastrophic cryoglobulinaemic vas-
culitis). The response to treatment has been a cure rate of 
30%, a partial response rate of 50% and no response in 
20% [17].
AKI may also occur in the absence of cryoglobulinaemia, 
both in native and transplanted kidneys. There is strong 
evidence, based on observational studies (one of which 
includes over 4 million hospitalized patients), that HCV 
infection is a significant risk factor for dialysis-requiring AKI 
in many settings including sepsis, myocardial infarction, 
HIV infection and others [18]. 
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HCV is also a risk factor for several acute post-transplant 
complications including acute transplant glomerulopathy, 
acute vascular rejection and TMA. HCV-associated cirrhosis 
can cause AKI by several mechanisms including the hepa-
torenal syndrome, hypovolaemia and sepsis.
AKI has been reported with several therapeutic agents 
used for HCV. Interferon may cause acute interstitial 
nephritis and the first-generation DAAs are known 
transiently to reduce the glomerular filtration rate. They 
may raise  serum creatinine levels by competition with its 
tubular secretion via the organic cation transporter-2 
(OCT-2 ) [19]. However, true AKI has also been reported 
with telaprevir, and less often with boceprevir [20].
The second-generation DAAs seem to be safer, yet there 
have been several reports that incriminate sofosbuvir in 
AKI [21]. In all reported cases, AKI was reversible after 
discontinuation of treatment, or even without it. In our 
own experience, this has not always been the case; several 
patients needed dialysis and a few progressed to CKD 
[unpublished data]. Time will tell if these observations are 
confirmed in other series.
HcV-rELAtED GLOMErULONEPHrItIs
HCV is associated with several types of chronic kidney 
involvement. The most common is membranoproliferative 
(mesangiocapillary) glomerulonephritis (MPGN), usually 
related to type II cryoglobulinaemia. MPGN may also 
develop in the absence of cryoglobulinaemia. Other forms 
of glomerular disease include IgA nephropathy (IgAN), 
membranous nephropathy (MN), postinfectious glomeru-
lonephritis, TMAs, focal segmental glomerulosclerosis 
(FSGS), and fibrillary and immunotactoid glomeru-
lonephritis [22]. Overall, HCV-associated glomerular 
disease is infrequent and the rate of MPGN in HCV-positive 
patients has been reported at less than 1% [4].
The pattern of injury depends on the pathogenesis; thus, 
MPGN with positive staining for immunoglobulins and C3 
may result either from mixed cryoglobulin (monoclonal 
IgM against polyclonal IgG anti-HCV antibodies) deposi-
tion, or from the deposition of anti-HCV polyclonal 
immunoglobulins without cryo-properties. The latter 
mechanism is also incriminated in HCV- associated MN 
and IgAN, whereas FSGS is associated with direct tissue 
infection [23].
The improved understanding of the mechanisms of 
HCV-induced glomerular disease provides the opportunity 
for targeted approaches to treatment: (1) non-specific 
immunosuppressive therapy, targeting glomerular inflam-
mation (intravenous or oral corticosteroids and aza-
thioprine); (2) selective immunosuppressive therapy such 
as rituximab, targeting B cells that synthesize cryoglobulins; 
and (3) antiviral therapy, since HCV infection triggers the 
production of immune complexes and the ensuing vas-
culitis. The evidence regarding the role of antiviral agents 
was limited until recently as the disease is infrequent and 
classical antiviral therapy (interferon plus ribavirin) is less 
effective and safe in patients with kidney disease. Preliminary 
data suggest that DAAs are more effective and safer than 
interferon-based therapies, even in patients with HCV-
induced glomerular disease [24].
Patients with nephrotic syndrome, rapid loss of kidney 
function or an acute flare of cryoglobulinaemic disease 
should first be treated with immunosuppressive drugs 
(e.g. intravenous corticosteroids, rituximab, cyclophos-
phamide) and plasma exchange. Antiviral therapy (with 
DAAs) is recommended after the vasculitis is controlled. 
Patients with moderate proteinuria and slow loss of kidney 
function should receive DAAs first in order to achieve 
HCV RNA clearance [25]. Studies are in progress in order 
to ascertain to what extent DAAs reduce the need for 
immunosuppressive therapies among patients with HCV-
related glomerular disease. 
HEPAtItIs c AND PrOGrEssION OF 
cHrONIc KIDNEY DIsEAsE
Chronic HCV infection has been shown to be a risk factor 
for CKD and its progression in several studies from different 
continents [26] and in a large meta-analysis. Furthermore, 
insulin resistance, which is specifically associated with HCV 
genotypes 1 and 4, is associated with chronic HCV [27]. 
The incidence rate for developing kidney failure was 
signif icantly higher in patients with HCV infection and 
diabetes compared to a control group with diabetes only, 
suggesting an additive effect [27]. Interestingly, an inter-
ventional study demonstrated that interferon-based anti-
viral treatment for HCV infection was associated with 
improved renal and cardiovascular outcomes in diabetic 
patients [13], and more recently it was shown in patients 
with HCV genotype 1 infection that DAA treatment 
reverses insulin resistance. Preliminary data from the 
Kaiser–Permanente health system show that both inter-
feron-based and DAA treatment significantly decrease the 
risk for kidney failure in CKD patients achieving SVR [10]. 
Antiviral treatment also seems to have a favourable effect 
on survival in patients on HD [26]. 
In spite of the greater risk for CKD progression with HCV 
infection, antiviral therapy in patients with CKD lags far 
behind that of the general population. HCV treatment of 
CKD patients should therefore be an urgent priority in this 
new era, with several effective treatment options.
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HcV AND KIDNEY trANsPLANt 
OUtcOMEs
HCV infection has a significant negative impact on long-
term (10 years) patient and graft survival in kidney trans-
plant recipients. This might manifest in specific ethnic 
groups and be influenced by the genotype [28]. Anti-
thymocyte globulin (ATG) induction therapy has long-term 
patient and graft survival benefits without flares of  HCV 
infection [29]. HCV-positive recipients had better patient 
and graft survival when receiving grafts from HCV-negative 
than from HCV-positive donors; the latter option entails 
the risk of reinfection and/or super-infection with a dif-
ferent strain [28]. The recent availability of DAAs could 
cure HCV in transplant recipients, thus nullifying its delete-
rious survival impact [30].
Treating the HCV prior to transplantation is the preferred 
strategy, as HCV-positive recipients experience greater 
mortality during the post-transplant period. They may 
experience more hepatic and metabolic complications, 
infections, recurrence of the primary kidney disease and 
malignancies. The exception to this rule occurs where the 
acceptance of an HCV-positive donor markedly shortens 
the waiting time for kidney transplantation. The Spanish 
experience has shown that transplanting HCV-positive 
organs into HCV RNA-positive recipients is associated with 
good long-term outcomes [31]. 
Meanwhile, during the treatment of HCV in transplant 
recipients, one should be aware of interactions between 
immunosuppressive medications and  DAAs, as a result of 
interference with the intestinal and hepatic transporter 
proteins as well as the liver microsomal enzymes [32]. It is 
important to monitor transplant patients receiving DAAs 
for renal complications, including proteinuria and activa-
tion of the immune system with production of allograft 
reactive antibodies.        
trEAtMENt OF HcV IN sEVErE cKD
The second-generation DAAs, since their introduction in 
2014, were available to all patients except those with 
severe CKD. Indeed, sofosbuvir, the first drug to be FDA 
approved and the backbone of many DAA regimens, 
undergoes significant renal excretion (the other DAAs 
have minimal renal excretion) and is not approved for use 
below an estimated glomerular filtration rate (eGFR) of 
30 mL/min/1.73 m2 [33]. Other issues included the dialyz-
ability of drugs and the presence or absence of autoim-
mune disease. With the rapid evolution of DAAs, we are 
now witnessing an era of  interferon-free, sofosbuvir-free 
and even ribavirin-free regimens, which allows their use in 
all stages of CKD [34].
According to the AASLD (the American Association for 
the Study of Liver Diseases), for CKD patients stages 1–3 
(eGFR > 30 mL/min/1.73 m2), any of the approved DAA 
combinations can be used, with no dose adjustment (evi-
dence rating 1A; last updated September 2017) [35]. For 
the advanced stages of CKD, with the poor tolerability of 
ribavirin and the possibility of accumulation of sofosbuvir, 
the trend is towards non-sofosbuvir, ribavirin-free based 
regimens. For CKD stages 4 and 5 (eGFR < 30 mL/min/ 
1.73 m2), genotypes 1a, 1b or 4, a daily f ixed-dose 
combination of 50 mg elbasvir and 100 mg grazoprevir 
(Zepatier) can be used for 12 weeks (rating 1B). For CKD 
stages 4 and 5, genotypes 1–6, 300 mg glecaprevir/120 mg 
pibrentasvir (Mavyret) can be used for 8–16 weeks (rating 
1B). Sofosbuvir-based regimens are not mentioned in the 
guidelines and have shown increased risk of worsening 
renal function in this group of patients, though other 
studies demonstrated safety and efficacy at half-dose [36] 
as well as full-dose regimens [37]. There is no consensus 
on the dose of sofosbuvir in severe renal impairment and 
its use is off-label. However, in view of accumulating 
evidence on its use in this group of patients, it can be 
considered a third option in situations where non-sofos-
buvir-based regimens are unavailable.
summary of changes in the AAsLD 
guidelines since this consensus meeting
The AASDL and IDSA (Infectious Diseases Society of 
America) guidance has been updated for patients with 
severe kidney impairment and recommends no dose 
adjustment for any DAA regimen used, including sofos-
buvir-based regimens [38].
For elbasvir/grazoprevir-based regimens, the C-SURFER 
trial demonstrated high efficacy in patients with advanced 
CKD, including patients on haemodialysis, with no signifi-
cant increase in adverse events [38]. For glecaprevir/
pibrentasvir, an integrated analysis of the EXPEDITION-4 
and EXPEDITION-5 studies confirmed very high SVR12 
in patients with genotypes 1–6 and CKD stages 3b–5, 
including patients on haemodialysis [38]. For sofosbuvir-
based regimens, a systematic review of 717 patients with 
HCV and CKD stages 4–5 found high efficacy (97% SVR12 
and SVR24) and good safety data (adverse event rate 
4.8%). Based on these and other data, no dose adjustment 
for sofosbuvir-based regimens is recommended [38].
trEAtMENt OF HcV IN KIDNEY 
trANsPLANt PAtIENts
The cure of HCV can be achieved in CKD stages 4–5, 
including dialysis patients and kidney transplant recipients. 
The choice of DAA regimen should be based on HCV 
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genotype, viral load, eGFR, concomitant medications, 
comorbidities and transplantation candidacy. The timing of 
the treatment (before or after transplantation) should be 
decided in collaboration with the transplant centre.
Multiple studies, summarized below, have shown successful 
HCV treatment after renal transplantation; sofosbuvir plus 
ledipasvir, simprevir or daclatasvir could be used with/with-
out ribavirin. Careful attention should be devoted to the 
risk of interactions with immunosuppressive medications. 
There is still no consensus on the use of the more recent 
drugs Zepatier and Mavyret post-transplantation.
1)   20 HCV RNA-positive kidney transplant recipients 
participated in a study in which a DAA regimen was 
initiated an average of 888 days post-transplant. The 
regimen included sofosbuvir and simprevir. The patients 
were mostly (88%) infected by genotype 1 and 50% 
had advanced hepatic fibrosis. All patients had SVR12 
[39].
2)   29 HCV RNA-positive kidney transplant recipients 
were given sofosbuvir and another drug for 12 weeks 
or 24 weeks; 88% of patients had viral clearance after 
4 weeks and 100% at treatment end. All patients had 
SVR12 [40].
3)   In a single-centre retrospective cohort of 31 kidney 
transplant recipients, patients were treated for 12 
weeks by DAA (mainly sofosbuvir with ledipasvir); 
SVR12 was 97%. No change was observed in eGFR 
but 19.3% of the patients had worsening of proteinuria 
after starting therapy [41]. 
4)   The transplanting hepatitis C kidneys into negative 
kidney recipients (THINKER) pilot trial showed that 
transplantation of HCV genotype 1-infected kidneys 
into HCV-negative recipients, followed by the use of 
DAAs, can provide good allograft function with a cure 
of HCV infection in patients after transplantation [42].
ADVErsE EFFEcts OF DIrEct-ActING 
ANtI-HEPAtItIs c tHErAPY
DAAs generally have a good safety profile. The commonest 
adverse events (headache, fatigue, nausea, diarrhoea) are 
tolerable and do not require dose modification. However, 
in advanced cirrhosis, caution should be exercised since 
hepatic decompensation and life-threatening events can 
occur, particularly with the use of protease inhibitors. In 
addition, a variety of specific adverse events were reported, 
albeit rare. These include pulmonary hypertension, acute 
interstitial nephritis and hyperbilirubinaemia [43].
Pregnancy should be avoided while on DAA therapy and 
strictly prevented if ribavirin has to be included, even when 
taken by the male partner. Pregnancy can be considered a 
few weeks after SVR, except if ribavirin was used, when it 
should be avoided for 6 months [44].
HcV cOINFEctION WItH  
OtHEr PAtHOGENs
The association of HCV infection with other viral infections 
may be associated with worse outcomes. Physicians should 
also be aware of the risk of drug–drug interactions [35].
a)   HCV–HBV. Both HBV and HCV are transmitted 
parenterally, and coinfection is not uncommon in Asia, 
sub-Saharan Africa and South America, and among 
subjects at high risk of parenteral transmission [45]. Few 
studies have investigated the mechanisms of the inhi-
bition of HBV replication by HCV. Shih et al. reported 
that HBV mRNA and antigen expression was asso-
ciated with a 2–4-fold reduction in the presence of 
HCV, and HBV particle secretion was suppressed up to 
20-fold [46]. The use of interferon-free DAAs for 
hepatitis C infection may be complicated by reactiva-
tion of occult hepatitis B and this risk should always be 
considered [47]. There may also be spontaneous 
clearance of hepatitis C. Female gender, coinfection 
with hepatitis B and IL28 genetic polymorphisms are 
associated with higher rates of spontaneous clearance 
of HCV [48].
b)   HCV–HIV. Among HIV-infected individuals in 2015, an 
estimated 2.3 million had also been infected with HCV. 
Liver diseases are a major cause of morbidity and 
mortality among these  coinfected patients and effective 
treatment of  both HIV and HCV is  a clear priority [49]. 
In a recent meta-analysis, HCV–HIV coinfection was 
associated with increased cardiovascular disease [50]. 
Moreover, HCV coinfection is associated with an 
increased risk of reduced GFR and/or proteinuria 
among HIV-infected individuals [51].
c)   HCV–schistosomiasis. Concomitant schistosomiasis and 
HCV infection is common in Egypt and some other 
developing countries. Coinfected patients exhibit a 
unique clinical, virological and histological pattern with 
high HCV RNA titres, higher liver biopsy necro-inflam-
matory and fibrosis scores, and markedly accelerated 
disease progression once chronic HCV infection is 
established.
HEPAtItIs c IN sUb-sAHArAN AFrIcA: 
tHE NIGErIAN EXPErIENcE 
Continental Africa has an HCV incidence rate of 31/100,000, 
with most of the infections occurring in North Africa. In 
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Nigeria, HIV and hepatitis B infections have received dis-
proportionately more attention than HCV infection. From 
1999 onwards, routine testing for HCV in blood banks 
started in Nigeria. Currently, there are no nationwide 
prevalence studies on HCV but multiple prospective cross-
sectional studies in different populations, and case control 
studies in patients with liver diseases and HIV infection 
have been conducted. HCV prevalence ranges from 0.4% 
in a population of pregnant women [52] to 14.7% in an 
HIV-infected population [53]. The prevalence in patients 
with advanced CKD is not well known. Reports from some 
renal centres in Nigeria quote prevalences ranging from 
0.3% to 2.5%, with genotypes 1 (85%) and 2 (15%) being 
the most common [54]. Few or no data exist on HCV and 
non-dialysis CKD in Nigeria.
HEPAtItIs c IN NOrtH AFrIcA:  
tHE EGYPtIAN EXPErIENcE
Egypt has one of the highest prevalences of HCV in the 
world. A national survey conducted in 2015 showed that 
about 10% of the population is chronically infected. It has 
been estimated that around 650,000 patients have cirrhosis, 
16,000 have developed HCC and some 30,000 people 
die from HCV annually. A national plan of action for the 
management of viral hepatitis was launched in 2006, and 
was intensified in 2014 with the introduction of the DAAs. 
DAAs were introduced at 1% of the price in western 
countries and, later, locally manufactured generics became 
available at 0.1% of the price. The current focus is on the 
prevention of new infections and national screening to 
diagnose and treat patients who are unaware of their 
infection. The reported prevalence may thus be an under-
estimate. It is hoped that HCV will be eradicated in Egypt 
by 2025 [55].
cONcLUsIONs
HCV infection is an important cause of morbidity and 
mortality in the various CKD populations. With the current 
availability of highly effective and well-tolerated DAA regi-
mens, CKD patients should be a priority target for “micro-
elimination“ of HCV, as an important step towards the 
WHO target of the elimination of viral hepatitis as a public 
health problem by 2030. Every country should have an 
action plan, and should be inspired by the impressive 
progress made by Egypt, where this IFKF meeting was held.
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